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We describe the design and operationalization of a blinded corticosteroid-tapering regimen for a randomized trial of tocilizumab
in giant cell arteritis (GCA). To our knowledge, no clinical trial in any disease has ever employed a blinded corticosteroid-tapering
regimen, but this was necessary to the design of our trial which is likely to be relevant to other investigations of steroid-sparing
regimens. Two standardized corticosteroid-tapering regimens are required for this GCA trial: a 6-month regimen in 3 arms (taken
with tocilizumab 162mg subcutaneously weekly or every other week or with placebo) and a 12-month regimenwith placebo (fourth
arm). Investigators select initial prednisone doses, tapered in an open-label fashion until 20mg/day. Doses <20mg/day are blinded.
At least 27 blinded blister packs are required to ensure blinding and encourage compliance. This permits all possible daily doses
but requires ≤5 capsules/day. The number of capsules taken at any point during tapering is identical across groups. Our approach
may be extrapolated to trials beyond GCA.
1. Introduction
Corticosteroids, used either alone or in combination with
other immunosuppressivemedications, remain a cornerstone
of treatment for many inflammatory diseases. Corticosteroid
use crossesmultiple subspecialty borders.Thesemedications,
highly effective for many conditions, are regarded generally
as the anti-inflammatory agents with the swiftest onset of
effect. For some diseases, such as giant cell arteritis (GCA),
corticosteroids are the only type of medication known to be
effective.
A broad paradigm for the treatment of inflammatory
disease involves a strategy that initially employs high doses
of corticosteroid sufficient to control acute inflammation,
followed by tapering—usually over months—to lower daily
doses when possible. A significant percentage of patients in
many diseases, however, are unable to discontinue corticos-
teroid use because of disease recurrence [1, 2]. Although
corticosteroids are efficacious, they are regarded by physi-
cians and patients alike as a “double-edged sword” because
of their association with a broad spectrum of adverse effects
[1, 3, 4]. Such adverse effects include hypertension, glucose
intolerance, osteoporosis, cataracts, gastrointestinal bleeding,
proximal muscle weakness, skin thinning, psychosis, depres-
sion, heightened risk for infection, and a decrease in the
overall quality of life [1, 3–5].
The development of a range of noncorticosteroid ther-
apies that are effective in some immune-mediated diseases
offers the possibility of reducing dependency on corticos-
teroids. Agents that have a steroid-sparing effect would be
a welcome addition to the current treatment armamentar-
ium. However, the rigorous demonstration of steroid-sparing
effects involves the conduct of randomized, double-blind
trials. Herein lies a significant hurdle: to our knowledge, no
clinical trial involving the double-blind administration of a
variable-dose, variable-tapering rate corticosteroid regimen
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Figure 1: GiACTA study design featuring standardized prednisone-tapering protocols.
has ever been performed. Consequently, the logistical issues
for designing, operationalizing, and conducting such a trial
have never been undertaken.
GCA, a form of vasculitis that affects large and medium-
sized vessels, is characterized by headaches, ischemia-related
visual manifestations (including blindness), polymyalgia
rheumatica, claudication of the jaw and extremities, consti-
tutional symptoms, myocardial infarction, and stroke [6].
Corticosteroids are highly effective at controlling systemic
inflammation and preventing acute ischemic damage but are
less successful at maintaining remission. Between 50% and
80% of patients experience relapses during dose reduction
and require long-term corticosteroid courses [1, 6].
GiACTA is a multicenter, randomized, double-blind,
placebo-controlled trial designed to evaluate the ability of
tocilizumab to maintain disease remission and to reduce
cumulative corticosteroid exposure in patients with GCA
(ClinicalTrials.gov, number NCT01791153) [7]. The trial de-
sign required not only the blinding of tocilizumab but also the
blinding of corticosteroid regimens of 2 different durations
used in the trial. We describe here the challenges inherent in
the design of a clinical trial involving blinded corticosteroid
regimens and outline our approach to the development
and operationalization of the blinded corticosteroid-tapering
regimen used in the GiACTA trial.
2. Methods
2.1. Overview of the GiACTA Trial. The GiACTA trial design
has been published [7]. The trial population, when complete,
will consist of approximately 250 patients (as of December
1, 2014, 192 patients were enrolled). Enrolled patients are
assigned randomly to 1 of 4 groups (Figure 1). Two of these
groups receive tocilizumab at different doses plus prednisone
(6-month tapers), and the other 2 receive prednisone alone
with tapering regimens of either 6 or 12 months. The
treatment regimens in the 4 arms are as follows: arm A,
subcutaneous tocilizumab 162mg/week, combined with a 6-
month corticosteroid taper; armB, subcutaneous tocilizumab
162mg every other week, combined with a 6-month corticos-
teroid taper; armC, prednisone alone, 6-month taper; armD,
prednisone alone, 12-month taper [7]. Patients in arms C and
D receive subcutaneous tocilizumab placebo injections.
2.2. Institutional Review Board Approval and Informed Con-
sent. Each participating clinic will have institutional review
board oversight. All participants will give written informed
consent.
2.3. Prednisone Regimen in GiACTA. Corticosteroids are
administered in GiACTA according to a protocol-defined
prednisone-tapering schedule.The6-month taper is designed
to test the ability of tocilizumab tomaintain disease remission
at 1 year after the discontinuation of corticosteroids. Because
the optimal duration of corticosteroids in GCA is unknown,
an arm with a 12-month CS taper is also included. The 6-
and 12-month corticosteroid-tapering regimens approximate
closely those used in many inflammatory diseases, balancing
the goals of controlling active inflammation quickly but
tapering and eventually discontinuing prednisone within a
reasonable time frame to prevent potentially unnecessary
corticosteroid-induced adverse effects.
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Figure 2: Initial prednisone dose of patients entering the trial.
2.4. Identifying the Challenges Confronting Development of
a Blinded Prednisone Taper. Translating complex blinded
corticosteroid-tapering regimens to a format that could be
understood easily and followed reliably by both study site
staff and patients posed a number of challenges. First, the
final product had to be simple enough to be operational-
ized by more than 100 clinical trial sites across North
America and Europe, covering 15 different languages. The
prednisone/prednisone-placebo tablets had to be sufficiently
user-friendly so that patients could take the medication in
compliance with the protocol.
Second, patients are entering the trial at different pred-
nisone doses, based on the initial dose which the investigator
believes is necessary to control the disease. The dose could
range from 20mg/day to a maximum of 60mg/day. Further-
more,maintenance of the trial blind required that the number
of pills taken must be the same across all 4 arms on any day
of the taper, regardless of whether patients are assigned to the
6-month or the 12-month taper.
Third, prednisone tablets are manufactured in multiple
denominations, including 1mg, 1.5mg, 2.5mg, 5mg, 10mg,
20mg, and 60mg tablets. Creating identical placebos for
all doses would have substantially increased the cost of the
blinding process. In addition, the plan ultimately used would
have had to minimize the number of tablets any patient
was required to take on the same day. Finally, a system for
measuring compliance with the prednisone regimen had to
be created, and mitigation plans for tablet loss and noncom-
pliance had to be developed to ensure minimal impact on a
patient’s tapering regimen.
3. Results
3.1. Fundamental Decision about Prednisone Taper. Each
patient enters the trial on an open-label prednisone dose
between 20 and 60mg/day, chosen by the investigator based
on disease presentation. The initial prednisone dose selected
for the first 192 patients, shown in Figure 2, illustrates the
range of doses at entry.
The blinded portion of the prednisone taper does not
begin until the patient tapers to below 20mg/day. This
permits GCA patients who have active disease to be treated
immediately with corticosteroids, even as preparations are
made to enroll them in the trial. To permit an unbiased eval-
uation of the corticosteroid-sparing effects of tocilizumab,
however, patients and investigators are blinded to the pred-
nisone taper schedule below 20mg/day.
3.2. Use of Blister Packs. Blinding is achieved by the provi-
sion of encapsulated prednisone/placebo doses in numbered
blister packs (Figure 3). The total duration and cumulative
dose of prednisone therapy for each patient depend on the
initial dose at entry into the trial and on the treatment arm
to which the patient is assigned. The daily dose comprises
active prednisone capsules, prednisone-placebo capsules, or
a combination of both.
3.3. Development of Prednisone Packaging. Overencapsula-
tion of commercially available prednisone tablets is used to
preserve the trial blind. The prednisone manufacturer (Rox-
ane Laboratories Inc., Columbus, OH) was selected based
on acceptance by regulatory authorities and commercial
availability. Regulations require that tablets be an acceptable
size for swallowing and meet certain dissolution criteria
after overencapsulation. Each capsule contains 1 prednisone
tablet along with filling material to secure the tablet within
the capsule. Placebo capsules contain only filling material
but weigh approximately the same as those containing
prednisone. The protocol-mandated tapering regimens are
achieved using combinations of only 3 denominations of
encapsulated prednisone tablets—1mg, 2.5mg, and 5mg—
and the placebo capsules.
Generic prednisone tablets were overencapsulated at a
contract manufacturing organization (Fisher Clinical Ser-
vices Inc., Center Valley, PA). To gain stability data on the
capsules, technical prednisone batches without intention for
use in humans were manufactured and placed in the selected
primary packaging material (duplex-blister packs). After the
first analysis of each technical batch (1mg, 2.5mg, and 5mg
prednisone and placebo formulations), Roche Regulatory
Affairs was able to generate an Investigational Medicinal
Product Dossier for the Clinical Trial Application. The
same approach was applied to batches intended for use in
humans. Strict adherence to Good Manufacturing Practice
was followed throughout the process.
3.4. Uniformity across the 2 Tapering Regimens. The tapering
scheme is designed in weekly decrements. Capsules required
for any given week are placed between 1 and 5 vertical blister
strips on a single card held within a wallet containing all
the capsules required for 1 week. The 7 horizontal rows are
organized according to day, and each card has a spare row to
be used in the event a capsule is lost. To ensure blinding, the
number of capsules taken at any given point is identical across
the 6- and 12-month prednisone-tapering regimens. Multiple
weekly blister pack combinations (27 in all) are designed to
maximize convenience for patients and to foster compliance.
This approach ensures that the prednisone dose is typically 3
but never more than 5 capsules in a single day.
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Figure 3: (a) Final prednisone wallets developed and approved for the GiACTA study. (b) Illustration of the use of placebo capsules to ensure
blinding. Two separate weeks from the six- and 12-week prednisone tapering regimens are shown. Placebo capsules are used to ensure that
patients receive an equal number of capsules across both regimens, thus ensuring blinding. PBO: placebo.
3.5. Distribution of Prednisone Packs to Sites. An interactive
voice response system (IVRS) is used to distribute the
appropriate prednisone packs from depots to sites, ready for
the patient to collect at each study visit. At each monthly
study visit, patients are given 4 blinded steroid wallets, each
of which is to last 1 week. Each blister pack bears a unique
alphanumeric identifier that allows the IVRS to instruct
the sites on allocation of the appropriate blister packs. The
identifier also indicates the order in which the steroid wallets
are to be used. During dispensing, study staff can write
additional patient instructions on the prednisone wallets for
the sake of clarity. Figure 3 shows the final prednisone wallets
developed and approved by theQualityDepartment at Roche.
3.6. Training of Trial Site Staff. At investigators’ meetings
held in Boston and Berlin before enrollment began, the study
staff at each clinical site was trained on the corticosteroid-
tapering regimens and the approach to blinding.The training
consisted of video and lecture components and allowed the
staff to gain hands-on familiarity with the blister packs, the
wallets, and the overall plan for dispensing corticosteroids.
3.7. Patient and Investigator Guidance Documents. To facili-
tate investigator and patient comprehension of blister pack
use and to foster compliance, illustrated guidance documents
and patient diaries were provided (Table 1). Study site staff
received a booklet that provided guidance on prednisone
dispensation and administration and that described the
correct way to track dispensation and administration on the
electronic case report form. At enrollment, patients receive
a booklet that aids in their understanding of the prednisone
packaging design, offers instructions on compliance, and
provides problem-solving scenarios regarding blister pack
use.
3.8. Experience with Blinded Corticosteroid Tapering in the
Trial to Date. As the GiACTA study has progressed, sites and
patients have become familiar with the technical and logis-
tical issues of the blinded corticosteroid regimens. Among
the first 170 patients enrolled, errors have typically occurred
during the first fewweeks after enrollment and have consisted
of patients selecting the incorrect blister pack (𝑛 = 2), taking
an incorrect number of capsules/tablets (𝑛 = 1), missing
medication because of vacation (𝑛 = 1), initiating a new
dose on an incorrect day (𝑛 = 10), and incorrectly recording
medication intake (𝑛 = 13). None of the errors has resulted
in a major protocol deviation or necessitated discontinuation
of the corticosteroid regimen.
4. Discussion
The field of rheumatology and the treatment of all inflam-
matory diseases were revolutionized more than 6 decades
ago by the discovery of cortisone as a therapeutic agent
for rheumatoid arthritis [8]. Since then, corticosteroids
have been used extensively in essentially every specialty of
medicine and surgery for the treatment of patients with
inflammatory conditions. Corticosteroids have proven to be
life-saving drugs in many diseases. In patients with GCA,
for example, the administration of corticosteroids as soon as
the diagnosis is suspected contributes powerfully to initial
control of the disease and preservation of vision, the loss
of which is patients’ greatest fear. Nevertheless, the adverse
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effects associated with prolonged corticosteroid use, even
in relatively low doses, are substantial, and the side effects
associated with the long-term use of moderate doses are
unacceptable. Indeed, corticosteroid-associated morbidity is
viewed by patients as the single greatest impediment to good
quality of life [5].
With the advent of the biologic era of therapeutics for
inflammatory diseases, it is now conceivable that the need
for long-term reliance on corticosteroids to maintain disease
control can be obviated in many conditions. In kidney trans-
plantation, for example, a common goal now is to achieve
posttransplantation courses that are corticosteroid-free after
several weeks, particularly in the case of living-related
donor transplantation [9]. The development of “steroid-free”
remissions and the identification of new medications that
enable steroid-sparing approaches to treatment are important
goals in managing immune-mediated conditions. The most
rigorous manner of assessing the steroid-sparing ability of
a medication is through the conduct of randomized clinical
trials that make use of blinded corticosteroid regimens.
Several lessons from our approach can be extrapolated
to trials in other immune-mediated conditions in which
corticosteroid sparing is a therapeutic requirement, thereby
helping to address an important need in the area of inflamma-
tion. First, blinded corticosteroid tapers are feasible in clinical
trials, even in the setting of complex treatment protocols that
involve the blinding of an experimental medication (in this
case, tocilizumab). Second, depending on the specific features
of the disease under study and the clinical trial protocol,
blinding of all corticosteroid doses may not be necessary. In
GiACTA, the decision to blind prednisone doses only below
20mg/day was crucial to the implementation of an effective
design. Trials of other medications in other inflammatory
diseases may emulate this approach because the ability of
corticosteroids to control most inflammatory diseases does
not wane in most conditions until patients reach doses lower
than 20mg/day.Third, systematic programs for the education
of trial staff and patients about the use of the prednisone-
blinding methodology chosen are essential to the success of
such trials.
To our knowledge, this is the first clinical trial in any
disease to use blinded, variable-dose, variable-duration corti-
costeroid regimens. Our approach permitted us to overcome
significant technical and operational challenges to fulfill the
requirements of a complex clinical trial protocol.The creative
approaches to solving the logistical problems are necessary
to ensure an unbiased evaluation of the ability of tocilizumab
to serve as a steroid-sparing treatment in GCA. Adaptations
of this approach may find broad use in other trials designed
to investigate the steroid-sparing effect of new medications
and to limit the morbidity from corticosteroids endured by
patients with inflammatory conditions.
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